Inhibikase Therapeutics Inc (IKT) returns
Inhibikase Therapeutics returns over 5 years
$1,000 invested in Inhibikase Therapeutics five years ago was worth $129.82 at the close on October 30, 2026, with dividends reinvested: an average return of -33.5% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -24.6% | — | $754.26 | -0.9% |
| 3 months | -32.0% | — | $679.83 | +2.1% |
| Year to date | -24.4% | — | $756.10 | +11.7% |
| 1 year | +6.2% | — | $1,062 | +12.4% |
| 3 years | +78.2% | +21.2% | $1,782 | +88.5% |
| 5 years | -87.0% | -33.5% | $129.82 | +76.0% |
Inhibikase Therapeutics return by calendar year
| Year | IKT | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -24.4% | +11.7% | -36.1% |
| 2025 | -36.9% | +17.7% | -54.6% |
| 2024 | +155.9% | +24.9% | +131.0% |
| 2023 | -57.7% | +26.2% | -83.9% |
| 2022 | -66.0% | -18.2% | -47.8% |
| 2021 | -78.7% | +28.7% | -107.4% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: IKT financials
No forecast, no recommendation. This page describes Inhibikase Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.